The litigation centers on whether risk disclosures were inadequate, delayed, or minimized as off-label use of the drug for weight loss accelerated
Around 27% of employers encourage employees to obtain GLP-1s through a direct-to-consumer platform, while 21% are pushing workers to use their FSA, HSA or integrated HRA dollars for the treatments
Weight Loss: The Data At this time, there arent any published head-to-head obesity trials directly comparing oral semaglutide to orforglipron, says Maria Teresa Anton, MD, a board-certified internal medicine physician who specializes in endocrinology, diabetes, and metabolism with Pritikin Longevity Center in Miami
If you are uncertain about the appropriate angle, consult your healthcare provider or diabetes care and education specialist (CDCES)
At 43, Chauche was prescribed a weight-loss medication called Wegovyone of a new class of drugs that mimic a hormone responsible for insulin production
But if these medicines are effective when used according to their original instructions, why are so many people talking about microdosing them now
